The George Institute for Global Health, University of New South Wales, Sydney, NSW 2000, Australia.
Diabetes Australia, Sydney, NSW 2037, Australia.
Int J Environ Res Public Health. 2024 Oct 8;21(10):1330. doi: 10.3390/ijerph21101330.
Produce prescription programs can benefit both individuals and health systems; however, best practices for integrating such programs into the Australian health system are yet unknown. This study explored stakeholders' perspectives on the acceptability, potential design and integration of produce prescription programs for adults with type 2 diabetes in Australia. Purposive sampling was used to recruit 22 participants for an online workshop, representing six stakeholder groups (government, healthcare service, clinician, food retailer, consumer, non-government organisation). Participant responses were gathered through workshop discussions and a virtual collaboration tool (Mural). The workshop was video-recorded and transcribed verbatim, and thematic analysis was conducted using a deductive-inductive approach. Stakeholders recognised produce prescription as an acceptable intervention; however, they identified challenges to implementation related to contextuality, accessibility, and sustainability. Stakeholders were vocal about the approach (e.g., community-led) and infrastructure (e.g., screening tools) needed to support program design and implementation but expressed diverse views about potential funding models, indicating a need for further investigation. Aligning evaluation outcomes with existing measures in local, State and Federal initiatives was recommended, and entry points for integration were identified within and outside of the Australian health sector. Our findings provide clear considerations for future produce prescription interventions for people with type 2 diabetes.
生产处方项目既有益于个人也有益于卫生系统；然而，将此类项目融入澳大利亚卫生系统的最佳实践尚不清楚。本研究探讨了利益相关者对澳大利亚 2 型糖尿病成年人生产处方项目的可接受性、潜在设计和整合的看法。采用目的性抽样，通过在线研讨会招募了 22 名参与者，代表六个利益相关者群体（政府、医疗服务、临床医生、食品零售商、消费者、非政府组织）。通过研讨会讨论和虚拟协作工具（Mural）收集参与者的反馈。研讨会进行了视频录制并逐字转录，并采用演绎归纳法进行主题分析。利益相关者认为生产处方是一种可接受的干预措施；然而，他们确定了与上下文、可及性和可持续性相关的实施挑战。利益相关者对支持项目设计和实施所需的方法（例如，社区主导）和基础设施（例如，筛选工具）直言不讳，但对潜在的资金模式持不同意见，表明需要进一步研究。建议将评估结果与当地、州和联邦倡议中的现有措施保持一致，并确定澳大利亚卫生部门内外的整合切入点。我们的研究结果为 2 型糖尿病患者的未来生产处方干预提供了明确的考虑因素。
